Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lonza/Pasteuria agree bionematicide manufacturing deal

Swiss chemical company Lonza (Basel) has signed an agreement with US biopesticide company Pasteuria Bioscience (Alachua, Florida) for a process transfer and manufacturing plan to produce Pasteuria spp bacterial spores in Lonza’s biochemical plant in Kouřim, Czech Republic. Manufacturing is expected to start later this year. Pasteuria spp are soil bacteria and act as a bionematicide. Head of Lonza Biological Manufacturing John McGrath says that the collaboration fits well with Lonza’s existing technology and manufacturing expertise. “Lonza offers significant fermentation expertise as well as the ability to scale-up manufacturing in order to meet the global need for Pasteuria spp bionematicides,” says Pasteuria Bioscience’s chief technical officer Kelly Smith. In June, Syngenta entered into an exclusive global technology partnership with Pasteuria to develop bionematicide products based on Pasteuria spp ( Agrow No 619, p 4).

Topics

What to read next

UsernamePublicRestriction

Register

AG005200

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel